You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Lisocabtagene maraleucel

Showing 1 - 16 of 16
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic

Not yet recruiting
  • Recurrent Transformed Chronic Lymphocytic Leukemia
  • +7 more
  • Biospecimen Collection
  • +9 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
May 15, 2023

Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

Not yet recruiting
  • Refractory Aggressive B-cell Lymphomas
  • +12 more
  • Boston, Massachusetts
  • +1 more
Oct 13, 2022

Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Richter Syndrome Trial

Not yet recruiting
  • Recurrent Transformed Chronic Lymphocytic Leukemia
  • +2 more
  • Biopsy
  • +10 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

Not yet recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • +6 more
  • Bridging radiation therapy
  • +2 more
  • (no location specified)
Jan 4, 2023

Lymphoma, Non-Hodgkin, Lymphoma, Nonhodgkin, Lymphoma, B-Cell Trial in United States (lisocabtagene maraleucel)

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • +3 more
  • lisocabtagene maraleucel
  • Gilbert, Arizona
  • +40 more
Apr 22, 2022

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in United States (JCAR017 (lisocabtagene

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • +4 more
  • JCAR017 (lisocabtagene maraleucel) single-dose schedule
  • JCAR017 (lisocabtagene maraleucel) 2-dose schedule
  • Birmingham, Alabama
  • +24 more
Nov 21, 2022

Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma Trial in Seattle

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +8 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 30, 2022

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic Trial in United States (JCAR017 (lisocabtagene maraleucel),

Active, not recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Lymphoma, Small Lymphocytic
  • JCAR017 (lisocabtagene maraleucel)
  • +2 more
  • Birmingham, Alabama
  • +63 more
Nov 21, 2022

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

Primary Mediastinal Large B-cell Lymphoma (PMBCL), Primary Mediastinal Large B Cell Lymphoma, Primary Mediastinal Large B-Cell

Not yet recruiting
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • +5 more
  • Boston, Massachusetts
  • +1 more
Jun 28, 2023

Lymphoma, Non-Hodgkin Trial in Worldwide (Standard of Care, JCAR017)

Active, not recruiting
  • Lymphoma, Non-Hodgkin
  • Standard of Care
  • JCAR017
  • Phoenix, Arizona
  • +78 more
Jan 13, 2023

B-Cell Non-Hodgkin Lymphoma Trial in Seattle (Anakinra)

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • Anakinra
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 11, 2023

Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL) Trial (Fludarabine (30 mg/m^2), Cyclophosphamide (500 mg/m^2), CRG-022

Not yet recruiting
  • Cancer
  • Relapsed/Refractory Large B-cell Lymphoma (LBCL)
  • Fludarabine (30 mg/m^2)
  • +2 more
  • (no location specified)
Jul 25, 2023

Hematologic Malignancy Trial in Bologna

Recruiting
  • Hematologic Malignancy
    • Bologna, Italy
      Programma Dipartimentale Terapie Cellulari Avanzate
    Apr 17, 2023

    Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma Trial in Kaohsiung, Taipei

    Recruiting
    • Diffuse Large B Cell Lymphoma
    • +4 more
    • CD19-targeted chimeric antigen receptor T-cell
    • Kaohsiung, Taiwan
    • +2 more
    Oct 25, 2022

    Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy

    Recruiting
    • DLBCL
    • +8 more
    • Cardiac MRI
    • Bonn, NRW, Germany
      University Hospital Bonn
    Jun 11, 2022